about
Linking RAGE and Nox in diabetic micro- and macrovascular complicationsUrotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actionsEffect of central urotensin II on heart rate, blood pressure and brain Fos immunoreactivity in conscious ratsE-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-betamiR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression.Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failureUrotensin II, a novel peptide in central and peripheral cardiovascular control.Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout miceIncreased cardiac sympathetic nerve activity in heart failure is not due to desensitization of the arterial baroreflex.Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.Responses of cardiac sympathetic nerve activity to changes in circulating volume differ in normal and heart failure sheepThe AGE/RAGE axis in diabetes-accelerated atherosclerosis.The endothelin system and endothelin receptor antagonists.The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis.The neurochemical characterisation of hypothalamic pathways projecting polysynaptically to brown adipose tissue in the rat.Stimulation of cardiac sympathetic nerve activity by central angiotensinergic mechanisms in conscious sheep.Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.The emerging role of NADPH oxidase NOX5 in vascular disease.Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade.Leptin-target neurones of the rat hypothalamus express somatostatin receptors.Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice.A Novel Interaction Between Sympathetic Overactivity and Aberrant Regulation of Renin by miR-181a in BPH/2J Genetically Hypertensive MiceDiabetes and Hypertension Differentially Affect Renal Catecholamines and Renal Reactive Oxygen SpeciesSGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes MellitusMetabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture
P50
Q26795694-B181B462-D37B-40EB-864A-6D3226093169Q28190334-2B5BAC04-4C0D-4299-909B-4BDAA78C4931Q28569120-6F893660-D1CC-48C8-BE7A-A93DC7144688Q33930316-5A2FE349-C9AC-4558-9C01-980A999D9C34Q34448719-82DB1920-58A5-4AF6-8947-0BFDBF580570Q35834648-3D251A2D-6D2E-44E4-B1E9-A5EAA5B5ABFDQ35914486-E6FD40A3-69D8-4A1C-9A19-6BC96F3F84A1Q36109288-E28B3F65-DC26-4241-B61A-126A298FBDFFQ36157347-C96B3536-F84A-4199-8269-93DE92F0216CQ36842628-2F692B44-8605-4E1F-8442-8F2F77670ABEQ36877606-45C0C726-C318-46C4-8601-61590B66DD09Q37091107-72F841DA-F3FA-42C5-8D0D-28167E5D4543Q37962118-79C10357-13A6-43F7-A896-F739295087B2Q43253718-3ABAEBD6-764C-4D16-94D0-C3997121114DQ43257049-8158934D-A55D-4022-831F-B15DDDF80708Q43925591-D050B85D-D643-4C42-948D-B86A4146402DQ44748733-57144BA7-5A80-4B4B-A593-3F89B741EB3FQ46103013-954F3A5B-F600-4E44-AB81-3B5BBC1E061CQ46371672-6AC02C97-0179-4F32-9275-67C77F8F73A5Q46539844-F755F1F8-B96B-4861-B2A2-89ED83185B95Q48234937-3CD3D1BC-07FA-4F22-AE78-95868EECD3D9Q50796108-86043ED4-D38A-4E5C-9202-3E4EED86B12FQ50804043-B34E0FCC-C8EE-4650-B538-C69FC58C787DQ51037508-B18C3BD3-2AA6-4A0E-A97D-D1F1294C1A65Q54397160-542F5EE5-53B1-4350-98F1-478A58CA2090Q58415345-5DA30A3A-3514-420E-A635-0CF721FB5134Q64108760-D6074AE5-D47A-4D7C-BBC8-28FD07080990Q88383576-472B4940-E376-48B9-892A-4BE13FEB70CBQ88426325-663D4FCA-5092-4956-A009-B988738EDAC9
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna Watson
@ast
Anna Watson
@en
Anna Watson
@es
Anna Watson
@nl
Анна Уотсон
@ru
آنا واتسون
@ar
type
label
Anna Watson
@ast
Anna Watson
@en
Anna Watson
@es
Anna Watson
@nl
Анна Уотсон
@ru
آنا واتسون
@ar
prefLabel
Anna Watson
@ast
Anna Watson
@en
Anna Watson
@es
Anna Watson
@nl
Анна Уотсон
@ru
آنا واتسون
@ar
P106
P1153
7403383994
P21
P31
P496
0000-0001-5306-409X